Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6189915 | Bulletin du Cancer | 2016 | 11 Pages |
Abstract
Bleomycin is a cytotoxic antibiotic and a component of chemotherapy regimens of germ cell tumors and lymphoma. Bleomycin lung injuries occur in 10% of patients, and lead to severe interstitial pneumonia in 3% of patients. Pulmonary toxicity is related to endothelial cells injury induce by free radicals and inflammatory cytokines. Diagnosis of bleomycin-induced lung toxicity is based on the combination of clinical and radiological features, and requires to rule out differential diagnoses including pneumocystis. “Bleomycin-induced pneumonitis” is the most frequent pattern; eosinophilic pneumonitis and organizing pneumonia are rarer. Occurrence of bleomycin lung toxicity requires an immediate and often permanent discontinuation. Treatment is based on steroid. Regular clinical and pulmonary function tests monitoring are mandatory for early detection of bleomycin-induced lung toxicity.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Josette Biya, Annabelle Stoclin, Sandra Dury, Jérôme Le Pavec, Olivier Mir, Julien Lazarovici, Christophe Fermé, Maxime Annereau, Kenneth Ekpe, Christophe Massard, Jean-Marie Michot,